PHLOW CORP.

REVISE THE SCOPE OF EFFORT

THE PURPOSE OF MODIFICATION P00020 IS TO EXERCISE OPTION CLIN 0010 AND INCORPORATE CHANGES TO THE DESCRIPTION OF SERVICES FOR DOMESTIC PRODUCIBILITY OF ESSENTIAL MEDICINES.

CLIN 0005 SHALL BE INCREASED FROM $334,423,625.23 BY OBLIGATING $7,095,891.76 TO A CLIN VALUE OF $341,519,516.99.

CLIN 0024 SHALL BE INCREASED FROM $0 BY OBLIGATING $3,892,431.86 TO A CLIN VALUE OF $3,892,431.86.

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION PERIOD 2 FOR CLIN 0009 AND CLIN 0010 AT FULL VALUE.

THE PURPOSE OF THIS MODIFICATION IS TO ISSUE AN EXTENSION TO THE BASE PERIOD AND OPTION PERIOD 1, INCREMENTAL FUNDING AND ADDING COST OVERRUN ITEM OF G&A ON DIRECT LABOR.

ADD $7,730,713.39 TO THE TOTAL CONTRACT VALUE: $4,033,088.15 WILL BE ADDED TO CLIN 0003 (U.S.- BASED PRODUCTION OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) FOR COVID 19 MCMS/E

1. CHANGE THE PERIOD OF PERFORMANCE FOR OPTION PERIOD 1 AT CLIN 0007 FROM 05/18/2024 THROUGH 05/17/2025 TO 07/03/2024 THROUGH 07/02/2025. 2. EXERCISE CLIN 0007 OPTION PERIOD 1 AT THE FULL VALUE OF $19,897,589.16 AND PROVIDE

THE PURPOSE OF MODIFICATION P00008 IS TO: 1. EXTEND THE BASE PERIOD OF PERFORMANCE AT CLINS 0001, 0003, 0004, AND 0005, AT NO ADDITIONAL COST TO THE GOVERNMENT; 2. UPDATE AND CHANGE THE TITLE DESCRIPTIONS OF ALL OPTION PERIOD CLINS, CLINS 0006 THRO